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Summary
The complement system augments the humoral immune response, possibly by a mechanism that
involves the B lymphocyte membrane receptor, CR2, which binds the C3dg fragment of C3
and triggers several B cell responses in vitro. The present studydemonstrates that CR2 associates
with a complex of membrane proteins that may mediate signal transduction by ligated CR2.
Monoclonal antibodies to CR2 immunoprecipitated from digitonin lysates ofRaji B lymphoblastoid
cells a membrane complex containing CR2, approximately equimolar amounts of CD19, which
is a member of the immunoglobulin superfamily, and three unidentified components: p130, p50,
and p20. The complex, which was immunoprecipitated also with anti-CD19, couldbe dissociated
by Nonidet P-40, accountingfor its absence in previous studies ofCR2. Expression ofrecombinant
CR2 and CD19 in K562 erythroleukemia cells led to formation of a complex that contained
not only these two proteins but also p130, p50, and p20, and another component, p14. These
unidentified components of the CR2/CD19 complex coimmunoprecipitated with CD19 and
not with CR2 from singly transfected cells, indicating primary association with the former.
CD19 replicated the capacity of CR2 to interact synergistically with mIgM for increasing free
intracellular Call, suggesting that the complex mediates this function of CR2. Therefore, CR2
associates directly with CD19 to become a ligand-binding subunit of a pre-existing signal
transduction complex of the B cell that may be representative of a family of membrane protein
complexes. This interaction between the complement and immune systems differs from that between
immunoglobulin and Clq by involving membrane rather than plasma proteins, and by having
complement involved in the afferent phase of the immune response.
T
he B lymphocyte has membrane receptors by which it
responds to immunologic and nonimmunologic stimuli;
the former are members of the Ig superfamily, and the latter
are receptors of the complementsystem. Of the former, mem-
brane Ig (mIg)t mediates clonally restricted uptake of an-
tigen by the B cell, and MHC class II directs antigen pre-
sentation to T lymphocytes. In addition, mIg activates
phospholipase C (PLC) (1) by a pathway that involves gua-
nine nucleotide binding proteins (2) and protein tyrosine ki-
nases (3), and is a part of a multimolecular complex (4-6),
the other components being required at least for membrane
' Abbreviations used in this paper: CR, complement receptor; DTT,
dithiothreitol, mIg, membrane Ig; PLC, phospholipase C; SCR, short
consensus repeat.
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expression of mIg and possibly for signal transduction. The
Fcy receptor type II (FcyRII), another member of the Ig su-
perfamily, modulates this pathway by suppressing PLC acti-
vation by crosslinked mIg (7). MHC class II, which would
be ligated during cognate B-T cell interactions, also induces
translocation of protein kinase C to the nucleus (8), and
proliferation and differentiation of primed B cells (9).
These reactions of the B cell, which are fundamental to
the humoral immune response, do not require components
of the complement system, all of which are evolutionarily
distinct from the Ig superfamily. However, genetic or acquired
deficiencies of certain components of the classical pathway
are associated with diminished primary antibody responses
to T-dependentand -independent antigens (10-13), impaired
generation of memory B cells (14), low levels of certain Ig
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characterized by the presence of autoantibodies (16). Only
deficiencies of complement proteins that are involved in the
activation of C3 by the classical pathway, or of C3 itself, are
associated with altered immune responses, and activated C3
serves as the ligand for complement receptors on B cells. There-
fore, the complement system, which shares with the immune
system a common purpose of host defense against microbial
infection, can modulate B cell responses in vivo, and the in-
tersection between these two systems is likely to involve C3
receptors on B lymphocytes.
Proteolytic activation of C3 generates the Cab fragment
that covalently attaches to the activator of the complement
system. The bound C3b transiently serves as aligand for com-
plement receptor type 1 (CR1; CD35) before it is trimmed
down to the C3dg fragment, which has a new specificity
for CR2 (CD21). CR1 and CR2 are expressed by all mature
B cells (17, 18), are homologous structures encoded by closely
linked genes on chromosome 1832 (19-21), and contain a
tandemly repeating, 60-70-amino acid motif, termed the short
consensus repeat (SCR) (22-24). The most common forms
of CR1 and CR2 have 30 and 15 SCRs, respectively, that
constitute their entire extracytoplasmic domains, single mem-
brane spanning segments, and relativelyshort COON-terminal
cytoplasmic regions of 43 and 34 amino acids, respectively.
The tandemly aligned SCRs form filamentous structures (25,
26) that extend the ligand binding sites away from the plasma
membrane.
The potential of CR2 for augmenting B cell function has
been shown by the capacity of mAbs or polymeric C3dg to
induce B cell proliferation in the presence of T cell-derived
factors (27) or PMA (28), to primeB cells for mIgM-dependent
proliferation (29), and, when crosslinked to mIgM, as might
occur with immune complexes containing both C3dg and
antigen, synergistically to enhance increases in free intracel-
lular Cat+ concentration ([Ca2 +];) (30), perhaps by a pro-
cess related to that mediating modest increases in [Ca2+];
when CR2 is crosslinked alone (31) . Ligation of CR2 also
maintains the growth of human B lymphoblastoid cells in
suboptimal culture conditions (32, 33), and of murine B cells
that had been stimulated with LPS (34). Thus, CR2 meets
an essential requirement for a molecule that might link the
complement and immune systems, that of modulating B cell
function when ligated by a product of complement activation.
The possible association of CR2 with other membrane
proteins was assessed because the short cytoplasmic exten-
sion of CR2 seemed insufficient to mediate these multiple
B cell responses. In digitonin extracts of B lymphoblastoid
cells, CR2 was demonstrated to be a component of a mul-
timolecular complex that contains CD19, a member of the
Ig superfamily (35, 36) that is expressed throughout the on-
togeny of the B cell (37), and three to four other membrane
proteins. The additional, unidentified componentswere also
detected in K562 erythroleukemia cells in which the com-
plex was reconstituted by the transfection with CR2 and CD19
cDNA constructs. Therefore, there resides on B cellsa signal
transduction complex separate from the antigen receptor com-
plex that is comprised of B cell-restricted proteins, CR2 and
56
￿
CR2-CD19 Signal Transduction Complex of the BLymphocyte
CD19 ofthe complementand immune systems, respectively,
and other components that are also present in non-B cells,
where they may function in homologous signal transduction
complexes containing other ligand-binding components.
Materials and Methods
mAbs.
￿
The anti-CR2 mAbs HB5 (American Type Culture Col-
lection [ATCC], Rockville, MD) and OKB7 (Ortho Diagnostic
Systems Inc., Westwood, MA), the anti-CD19 mAbs B4 (37), 4G7
(Becton Dickinson, & Co., Mountain View, CA), and HD37 (Dako
Corp., SantaBarbara, CA), and DA4.4 anti-IgM (ATCC) were used.
Control antibodies for nonspecific immunoprecipitation were
RPC5.4 IgG2a (ATCC) and MOPC21 IgG1(Cappel Laboratories,
Malvern, PA).
Preparation of K562 Erythroleukemia Cells Expressing CR2 and
CD19. Replicate samples of 106 K562 cells, which had been
grown in RPMI supplementedwith 10% FCS, penicillin, and strep-
tomycin, were pelleted and resuspended with 1.5 ml of RPMI con-
taining 0.03 ml Lipofectin (Bethesda Research Laboratories,
Bethesda, MD) and either 38 wg ofpiCR2 (38) and 2 Etg pSVneo.1
for expression of CR2, or 40 hg ofpZipneo.SV(CD19) for expres-
sion of CD19. After culture for 24 h, 3 ml of RPMI with 20%
FCS was added and culture continued for 24 h. The cells were
washed, cultured for an additional 24 h in RPMI/10% FCS, and
then selected by growth in medium containing 400 ug/ml G418
(Gibco Laboratories, Grand Island, NY). The G418-resistant cells
were immunofluorescently stained with HB5 anti-CR2 or HD37
anti-CD19 and sorted for high CR2- or CD19-expressing cells by
use of a FACStar-Plus flow cytometer (Becton Dickinson & Co.).
K562 cells expressing both CR2 and CD19 were prepared by
cotransfection ofCR2-expressing cells with pZipneo.SV(CD19) and
p141, a plasmid conferring resistance to hygromycin, followed by
selection in medium containing 200 lug/ml hygromycin B
(Calbiochem-Behring Corp., San Diego, CA) . Cellsexpressing high
CD19 and CR2 were sorted by use of the FACStar-Plus.
Immunoprecipitation ofRadiolabeled Cells.
￿
Raji B lymphoblastoid
cells and K562 transfectants were surface labeled with 1251 (New
England Nuclear, Boston, MA) by a procedure that involves lysine
residues (39). Raji cells were labeled in vivo with 32pO4 (New En-
gland Nuclear), and replicate samples were incubated for 10 min
at 20°C in buffer alone or containing 100 ng/ml PMA (40) . Raji
cells were also labeled by culture for 16 h in methionine-depleted
medium to which had been added 0.1 MCi [31S]methionine (41).
Cellswere lysed in buffer containing 1% digitonin (Sigma Chem-
ical Co., St. Louis, MO) (42), 10 mM triethanolamine, pH 7.4,
150 mM NaCl, 1 mM EDTA, 5 mM DFP, 1 P,g/ml antipain, 1
hg/ml chymostatin, 1 p.g/ml pepstatin, and 1 t~g/ml leupeptin.
In the phosphorylation experiments, the digitonin buffer also con-
tained 10 mM NaF, 5 mM Na4P20,, 1 mM Na3VO4, 1 mM ATP,
and 100 p,g/ml DNAse (40). For lysis with 1% NP-40, this deter-
gent was substituted for digitonin.
For immunoprecipitation ofCR2, insoluble materialwas removed
by centrifugation of the lysates from 2 x 107 cells/0.6 ml lysis
buffer. The lysates were precleared twice by rocking at 4°C for
4 and 24 h, with 50 ul packed Trisacryl beads bearing protein A
(Pierce Chemical Co., Rockford, IL), and were divided into repli-
cate samples to which were added 10 wg HB5 and 10 jug RPC5.4
IgG2a, respectively, and 25 1A1 protein ATrisacryl beads. After
rocking for 1 h at 4°C, the beads were pelleted, washed, and eluted
into 0.1 ml of boiling sample buffer containing 6% SDS and 200
mM dithiothreitol (DTT) . For immunoprecipitation of CD19, 5hg HD37 or B4 anti-CD19, and MOPC21 IgGI were substituted
for HB5 and RPC5.4, respectively, and the complexes were recov-
ered with rabbit IgG anti-mouse Ig coupled to Sepharose (Dako
Corp.) . The eluates of all immunoprecipitates were analyzed on
5-15% SDS-polyacrylamide gradient gels. Two-dimensional non-
reducing/reducing gels were run on 5-20% gradient gels in the
first dimension without prior treatment with DTT, the gel lanes
were cut out, soaked in sample buffer containing 5% 2-ME for
1 h, and layered on a 5-20% gradient gel with a 3% stacking gel
for the second dimension . IEF/SDS gels were performed by the
method of O'Farrell (43) with the second dimension run in a 5-20%
polyacrylamide gradient .
Analysis of[Ca21], in Daudi Cells.
￿
Daudi B lymphoblastoid
cells were loaded with indo-1AM (Molecular Probes, Eugene, OR),
and incubated with mAbs specific for mIgM, CR2, and CD19,
respectively. The ratio of fluorescence at 400-415 nm to 485-500
nm was measured foreach cell by flow cytometry using the FACStar-
Plus and the Chronys Program (Becton Dickinson & Co .) . The
mean ratio for all cells in consecutive 10-s intervals was determined
for 20 s before and 140 s after addition of crosslinking goat F(ab') 2
anti-mouse Ig that had been previously adsorbed with immobi-
lized human IgM. These measurements were converted to mean
[Ca" J i (44) .
Results
CR2 and CD19 Are Components ofa Multimolecular Mem-
brane Protein Complex ofB Lymphocytes. Raji B lympho-
blastoid cells that had been surface labeled with 1251 were
solubilized in buffer containing digitonin, and immunoprecipi-
tates were prepared with two anti-CR2 mAbs, HB5 and
OKB7, and analyzed by SDS-PAGE . In addition to CR2 at
145 kD, four additional labeled proteins designated according
to their molecular masses as p130, p95, p40, and p20, respec-
tively, were specifically precipitated with bothHB5 andOKB7
(Fig . 1) . As HB5 andOKB7 recognize different epitopes on
CR2 (38), it is unlikely that the coprecipitating proteins were
present by crossreacting with the anti-CR2 mAbs .
The p95 coprecipitating with CR2 resembled the B cell-
specificmembrane protein, CD19, by molecular mass . There-
fore, replicate samples of a digitonin lysate of 1251-labeled
Raji cells were subjected to immunoprecipitation with mono-
clonal anti-CR2 and anti-CD19, respectively, followed by SDS-
PAGE . The anti-CR2 immunoprecipitated five proteins that
resembled those observed in the experiment depicted in Fig .
Figure 1 . Autoradiograph of SDS-
polyacrylamide gel ofimmunoprecipitates
obtained from digitonin lysates of 1251
surface-labeled RajiB lymphoblastoidcells
with HB5 anti-CR2 (lane 1), OKB7 anti-
CR2 (lane 2), and control RPC5.4IgG2a
(lane 3), respectively . The arrowheads in-
dicate the positions ofproteins specifically
immunoprecipitated by both anti-CR2
mAbs .
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Figure 2 . Autoradiograph of SDS-
polyacrylamide gel ofimmunoprecipitates
obtained from digitonin lysates of 1251-
labeledRaji B lymphoblastoid cells with
HB5 anti-CR2 (lane 1), control RPC5.4
IgG2a (lane 2), HD37 anti-CD19 (lane
3), and control MOPC21 IgGI (lane 4),
respectively.
1 (Fig . 2, lane 1) . The anti-CD19 recovered four of these
components, corresponding to CR2 at 145 kD and CD19
at 95 W, p130 and p20; p40 was not present (Fig. 2, lane
3) . The different relative intensities of the CR2 and CD19
bands in the anti-CR2 and anti-CD19 precipitates may be
caused by the approximately fivefold larger number ofCD19
than of CR2 molecules that are expressed by Raji cells, or
may indicate either that anti-CR2 does not recover all CD19
or that anti-CD19 does not recover all CR2 .
Prior studies that had demonstrated only CR2 in im-
munoprecipitates obtained with antibody of this specificity
from lysates ofB lymphocytes that had been surface labeled
with 1251 (45, 46) had used the nonionic detergents, NP-40
or Triton X100, for solubilizing membrane proteins. The role
ofdigitonin in maintaining theCR2/CD19 complex was as-
sessed by solubilizing replicate samples of 1251-labeled Raji
cells in digitonin and NP-40, respectively, and analyzing im-
munoprecipitates obtained either with anti-CR2 or anti-
CD19 . In the presence ofNP-40, anti-CR2 precipitated only
three proteins, CR2, p130, and p40 (Fig . 3 A, lane 2), of
the five that were seen in the presence of digitonin (Fig. 3
A, lane 1) . Similarly, in the presence of NP-40, anti-CD19
precipitated CD19 (Fig . 3 B, lane 2), but not CR2, p130,
and p20, which were present in immunoprecipitates prepared
from digitonin lysates (Fig. 3 B, lane 1) . Thus, the associa-
tion of CR2, CD19, and p20 is dependent on the use of
digitonin.
Figure 3. (A) Autoradiograph of SDS-polyacrylamide gel of im-
munoprecipitates obtained from digitonin lysates (lanes 1 and 3) and NP-
40 lysates (lanes 2 and 4) of 1251-labeled Raji cells with HB5 anti-CR2.
(B) Autoradiograph ofSDS-polyacrylamide gel ofimmunoprecipitates ob-
tained with HD37 anti-CD19 from replicate samples ofthe digitonin ly-
sates (lanes 1 and 3) and NP-40 1ysates (lanes 2and 4) of 1251-labeled Raji
cells .Figure 4 .
￿
Autoradiograph ofSDS-polyacrylamide gel of the membrane
protein reimmunoprecipitated by anti-CD19 from the NP-40/SDS eluate
of the complex obtained from digitonin lysates of 32PO 4-labeled, PMA-
treated Raji cells by anti-CR2 . Immunoprecipitates were obtained with
control RPC5 .4 IgG2a (lane 1) and HB5 anti-CR2 (lane 2), respectively,
from replicate samples of the digitonin lysate of in vivo 32P04-labeled Raji
cells. Thelatter was eluted by treatment with2% NP-40/0.2% SDS, and
the proteins remaining bound to the HB5-Sepharose were analyzed (lane
3) . The eluate was reimmunoprecipitated with HD37 anti-CD19 (lane
4) and control MOPC21 IgGl (lane 5), respectively.
To determine whether the membrane proteins coprecipita-
ting with CR2 could be phosphorylated in the presence of
PMA, and whether the 95-kD protein in the immunopre-
cipitate could be demonstrated to react with anti-CD19, Raji
cells were incubated with 32P04 and treated with PMA to
induce phosphorylation ofCR2 (40) . Anti-CR2 immuno-
precipitated from digitonin lysates ofthe Raji cells three phos-
phoproteins corresponding in molecular mass to CR2, p130,
and CD19 (Fig. 4, lane 2) . Treatment of a replicate sample
of the anti-CR2 immunoprecipitate with NP-40/SDS at 4°C
released the 95-kD protein from the complex (Fig . 4, lane
3), and this protein was specifically immunoprecipitated from
the NP-40/SDS eluate with anti-CD19 (Fig . 4, lane 4),
providing direct evidence for its identity as CD19 . The 130-
kD component of the complex was not released by NP-
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Figure 5 . Autoradiograph of SDS-
polyacrylamide gel ofproteins immuno-
precipitated by HB5 anti-CR2 (lane 1)
and control RPC5 .4 IgG2a (lane 2),
respectively, from digitonin lysates ofRaji
cells biosynthetically labeled with [3 5S]-
methionine.
40/SDS, consistent with its coprecipitation withCR2 in the
presence of NP-40 (Fig. 3) .
Raji cells were biosynthetically labeled with [ 35S]methio-
nine, and immunoprecipitates were prepared with HB5 anti-
CR2 from digitonin lysates . In addition to CR2 and CD19
at 145 and 95 kD, respectively, labeled proteins corresponding
in molecular mass to p40 and p20 were specifically immuno-
precipitated (Fig. 5) ; a protein at 14 kD was present that had
not been observed with 1251 labeling. Biosynthetic labeling
with [35S]methionine or a mixture of [ 35S]methionine and
[ 355]cysteine (data not shown) did not lead to the detection
of a 130-kD protein, suggesting a low molar ratio of the
1251- and 32PO4-labeled protein of this molecular mass rela-
tive to the other components of the complex . Assuming com-
parable half-lives of 14 h for CR2 (41) and CD19 in B lym-
Figure 6 .
￿
Flow cytometric analysis ofRaji cells (a) and
K562 cells stably expressingrecombinant CR2 (b), recom-
binant CD19 (c), or CR2 and CD19 (d) that had been
indirectly stained with control antibody (dotted line), HB5
anti-CR2 (solid line), or HD37 anti-CD19 (dashed line)
followed by fluorescein-conjugated goat anti-mouse Ig .phoblastoid cells, we determined their molar ratio in the
complex by densitometric scanning of the gels, revealing a
CD19/CR2 labeling ratio of 0.8 . Based on the presence of
12 and 16 methionines in CD19 (36) and CR2 (23, 24), respec-
tively, the molar ratio of these proteins in the complex is
calculated to be ti1:1 . This stoichiometry suggests that most
molecules ofCR2 are contained within complexes with CD19,
and that most molecules ofCD19 are not associated withCR2 .
Reconstitution ofthe CR21CD19 Complex in K562 Erythro-
leukemia Cells. CR2 and CD19 are expressed primarily by
B lymphocytes, but the cellular distribution of the other com-
ponents of the complex is unknown . To determine whether
expression of CR2 and CD19 in a cell type other than the
B cell would result in the association of these two proteins
and in the recovery ofthe additional components ofthe com-
plex, K562 erythroleukemia cells were singly or doubly trans-
fected with cDNA constructs encodingCR2 and CD19 . The
amounts ofCR2 and CD19 present on the transfectants were
assayed by flow cytometric analysis ofcells stained with mAbs
and found to be comparable with that on Raji cells (Fig. 6) .
Only CR2 orCD19 was expressedby the relevant single trans-
fectants, indicating that neither membrane protein requires
the other for transport to the plasma membrane ; all double
transfectants expressed bothCR2 and CD19, the latter being
present in molar excess over former, as occurs in Raji cells.
Immunoprecipitates prepared with anti-CR2 from digitonin
lysates of 1251-labeled, doubly transfected K562 cells revealed
the presence not only of CR2 and CD19, but also of pro-
teins of 130, 40, and 20 kD (Fig. 7, lane 1) that were iden-
tical in molecular mass to the coprecipitating components
of the complex in Raji cells (Fig. 7, lane 7) . Thus, the entire
complex that had been immunoprecipitated with anti-CR2
from lysates of Raji cells could be recovered from K562 cells
by transfection only of CR2 and CD19 .
Figure 7 .
￿
Autoradiograph of SDS-polyacrylamidegel ofmembrane pro-
teins immunoprecipitated with HB5 anti-CR2 (lanes 1, 3, and 5) and control
RPC5.4 IgG2a (lanes 2, 4, and 6), respectively, from digitonin lysates of
1251-labeled K562 cells expressing recombinant CR2 and CD19 (lanes 1
and 2), recombinantCR2 alone (lanes 3 and 4), and recombinant CD19
and (lanes 5 and 6). The immunoprecipitates obtained with anti-CR2 (lane
7) and RPC5.4 IgG2a (lane 8) from the digitonin lysate of 1251-labeled
Raji cells are shown for comparison .
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Immunoprecipitates prepared with anti-CR2 from digitonin
lysates ofK562 cells transfected only with CR2 cDNA con-
tained CR2, p130, and p40, but not p20 (Fig. 7, lane 3),
indicating that p130 and p40 associate primarily with CR2
and do not require CD19 either for their surface expression
or coprecipitation. In contrast, the absence of p20 suggests
a primary association with CD19. No specific proteins were
recovered with anti-CR2 from lysates of the CD19 single
transfectants (Fig. 5, lane 5), providing additional evidence
that the proteins coprecipitating withCR2 were not present
because of crossreactivity with anti-CR2 .
Immunoprecipitates obtained with anti-CD19 from digi-
tonin lysates of the 1251-labeled doubly transfected K562 cells
also contained all the components of the complex from Raji
cells, except p130, whichmay have been obscured by theCD19
band, and the40-kD component (Fig. 8, lanes 1 and 7) . The
p20 component was enriched in the anti-CD19 immuno-
precipitate when compared with its relative amount in the
anti-CR2 immunoprecipitate, suggesting that it may associate
with CD19. An additional 14-kD protein was present that
had not been observed in 1251-labeled immunoprecipitates
prepared either with anti-CR2 or anti-CD19 from Raji cells,
or with anti-CR2 from the doubly transfected K562 cells.
This component was similar in molecular mass to a [35S]me-
thionine-labeled protein coprecipitating with CR2 from Raji
cells (Fig . 5) .
The possibility that p20 associates withCD19 rather than
CR2 was confirmed by analysis of the anti-CD19 im-
munoprecipitates from the digitonin lysates of 1251-labeled
K562 transfectants expressing onlyCD19 ; not only was CD19
recovered, but also the p20 and p14 components (Fig . 8, lane
5) . A protein of 50 kD also was present in the anti-CD19
immunoprecipitates ofK562 cells expressing CD19 alone or
with CR2 . This component, which probably was present
in complexes obtained with anti-CR2 from doubly trans-
Figure 8.
￿
Autoradiograph ofSDS-polyacrylamide gel ofmembrane pro-
teins immunoprecipitated with HD37 anti-CD19 (lanes 1, 3, and 5) and
control MOPC21 IgGI (lanes 2, 4, and 6), respectively, from digitonin
lysates of 1u14abeled K562 cells expressing recombinant CR2 and CD19
(lanes 1 and 2), recombinantCR2 alone (lanes 3 and 4), and recombinant
CD19 alone (lanes 5 and 6). The immunoprecipitates obtained with anti-
CD19 (lane 7) and MOPC21 IgGI (lane 8) from the digitonin lysate of
1 251-labeled Raji cells are shown for comparison .fected K562 cells (Fig. 7, lane 1) or Raji cells (Fig . 7, lane
7), also associates with CD19 because it coprecipitated with
anti-CD19 from the CD19-expressing K562 cells (Fig . 8, lanes
1 and S), but not with anti-CR2 from the CR2 single trans-
fectants (Fig. 7, lane 3) . The p40 component was absent from
anti-CD19 immunoprecipitates, in keeping with its primary
association with CR2. In summary, analysis ofthe K562 trans-
fectants indicates that five membrane proteins that are ex-
pressed by this cell type interact with theB cell-specific mem-
brane proteins, CR2 and CD19 .
To determine whether the p20 component ofB cells resem-
bled that of K562 cells with respect to charge and associa-
tion withCD19 in the absence ofCR2, immunoprecipitates
were obtained with anti-CD19 from the CR2- L4 subclone
ofRamos cells and fromK562 cells that had been singly trans-
fected with CD19 and were subjected to two-dimensional
IEF/SDS gels . The CD19 component from both cells was
present in the acidic and basic regions of the gel, in which
a relatively narrow pH range of 5-7 was used, perhaps
reflecting differential glycosylation and phosphorylation (Fig.
9) . The p20 component was recovered from the L4 cells, in-
Figure 9.
￿
Autoradiograph of the two-dimensional gels (IEF in the first
dimension, SDS-polyacrylamide gel in the second dimension) of 1251-
labeled membrane proteins immunoprecipitated with HD37 anti-CD19
from digitonin lysates of the CR2- L4 subclone of the Ramos Burkitt
lymphoma line and of K562 cells expressing recombinant CD19. Arrows
indicate positions of CD19, p20, and p14 ; the last was expressed only in
the K562 cell.
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dicating its association with CD19 in the B cell lineage, and
its pattern on IEF, resembled that of p20 from K562 cells
(Fig. 9) . Thus, p20 of B cells andK562 erythroleukemia cells
are likely to be identical .
Membrane proteins coprecipitating with anti-CR2 and
anti-CD19 from 1251-labeled Raji cells and K562 cells, re-
spectively, were analyzed by two-dimensional, nonreducing/
reducing gels. No components appeared to be disulfide-linked
homo- or heterodimers because all proteins fell on the di-
agonal (Fig. 10) .
Crosslinking CD19 to m1gM Synergistically Increases (Ca2 +];,
Replicating an Effect ofCR2. The function of the complex
containing CR2 and CD19 was examined by determining
whether CD19 shared with CR2 a capacity for synergisti-
cally increasing [Cal+]i when crosslinked to mIgM on B
cells. Replicate samples ofDaudiB lymphoblastoid cells that
had been loaded with indo-1 were preincubated with optimal
and suboptimal concentrations of murine monoclonal anti-
IgM, and with saturating concentrations of anti-CR2 and
anti-CD19 individually and in combination with suboptimal
anti-IgM, respectively . Goat anti-mouse Ig was added to cross-
link the cell-bound mAbs, and [Cal+]i was monitored by
flow cytometry . Ligation ofmIgM with the higher and lower
concentrations ofmAb caused eightfold and twofold incre-
ments in [Ca2+]i, respectively (Fig. 11) . Crosslinking CR2
alone had no effect on [Ca2+];, whereas crosslinking the
receptor to suboptimal amounts of anti-IgM synergistically
increased [Ca2 +] i by fourfold . Crosslinking CD19 alone
caused a two- to threefold increment in [Ca2
+]i, and a syn-
ergistic rather than additive effect was obtained when CD19
was crosslinked to suboptimal anti-IgM, increasing [Ca2+ ],
almost to the level seen with cells stimulated with the op-
timal concentration of anti-IgM .
Daudi B lymphoblastoid cells express an excess of CD19
relative to CR2, so that it is not possible to state whether
the CD19-mediating synergy was present in complexes con-
taining or lacking CR2 . Although development ofCR2- and
CD19-deficient B cell lines is required to resolve these two
Figure 10 .
￿
Autoradiograph of two-dimensional gel of membrane pro-
teins immunoprecipitated withHD37 anti-CD19 from a digitonin lysate
of 1251-labeled K562 cells run in the first dimension without reduction
and in the second dimension after reduction of disulfide bonds.Figure 11.
￿
Synergistic increases in [Ca2*]i induced by crosslinking CR2
and CD19, respectively, to mIgM on Daudi B lymphoblastoidcells. Daudi
cells that had been loaded with indo-1 were preincubated with the mAbs
Fab DA4.4 anti-IgM at optimal (2 Kg/ml) (O) and suboptimal (0.004
p,g/ml) (") concentrations, F(ab')2 HB5 anti-CR2 ((]) and IgGI 4G7
anti-CD19 (A), individually and inthe combinations, anti-CR2 with subop-
timal anti-IgM (/), and anti-CD19 with suboptimal anti-IgM ("). At
the arrow, goat F(ab')2 anti-mouse Ig was added, and fluorescence was
monitored by flow cytometry.
possibilities, the latter may be considered more likely because
of the capacity of CD19 to increase [Ca2+]i when ligated
alone and to induce a more marked increase in [Ca2 +]i when
ligated to mIgM. With either type of complex, synergistic
interaction of CD19 with mIgM suggests that this function
of CR2 may reflect its interaction with CD19, which, with
its associated components, may be the signal transducer.
Discussion
The present study suggests that the complement system
may modulate B cell function through a nonantigen receptor
complex that may be representative of a family of receptor
complexes found on other cell types. Three findings support
this proposal: CR2 is a component of a complex of mem-
brane proteins on the B cell; one of the associated proteins
is CD19, a member of the Ig superfamily; and at least one
of the other components, p20, interacts with CD19 rather
than CR2 and is expressed by the K562 erythroleukemia cell
line. The first observation provides a response to the problem
that initiated these experiments, which was to understand
the mechanism of signal transduction by a membrane pro-
tein having only 34 amino acids in its cytoplasmic domain.
The second observation provides a potential molecular site
of interaction when complement modulates the immune re-
sponse. The third finding suggests that the CD19 complex
of the B cell may be representative of a family of complexes
having identical subunits, such as p20, and unique subunits
that may be homologues of CD19. The occurrence of such
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complexes on non-B cells may indicate that the CD19 com-
plex has an important role in the antigen-independent bi-
ology of the B cell, perhaps during development in the bone
marrow before expression of mlg.
A complex having the composition, CR2/CD19/p20/
(p50)/(p14), designated the CR2/CD19 complex (Fig. 12),
was immunoprecipitated with anti-CR2 from digitonin ly-
sates of Raji B lymphoblastoid cells (Figs. 1-3, 8, and 9).
Only the first three components are considered to be definite
members of the complex. CR2 and CD19 had an ti1:1 molar
ratio when antibody to the limiting component, CR2, was
used for immunoprecipitation (Fig. 5), and the intensity of
indirect iodination of lysines of p20 relative to that of CR2
and CD19 was consistent with substantial amounts of this
component in the complex. Also, neither CD19 nor p20
coprecipitated with anti-CR2, nor CR2 and p20 with anti-
CD19 in the presence of NP-40 (Fig. 3), making unlikely
the possibility that the additional two components were cross-
reacting with the immunoprecipitating antibodies or that p20
represented a proteolytic fragment of CD19. The inclusion
of the p50 component in the complex is based primarily on
its distinct appearance in immunoprecipitates from K562 cells
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I
￿
--I r- I
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n
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containing CR2 and CD19. The CR2/p40 complex is not considered to
associate with CD19 because p40 coprecipitated only with anti-CR2 and
not with anti-CD19. The CR2/CD19 complex is considered to contain,
in addition to these components, p50, p20, and p14. The p50 and p14
components are shown in parentheses because the former has not been
clearly identified in Raji cells, and the relationship between the [35S]-
methionine-labeled p14 of Raji cells and the 125I-labeled p14 of K562 cells
is not known. This complex may augment increases in [Ca2*]i induced
by mIgM. The CD19 complex resembles the CR2/CD19 complex physi-
cally and functionally, except for the absence of CR2. The p130 compo-
nent associates with either CR2 or CD19, but its limited presence in the
complexes suggests that it may not be essential for their function.(Fig. 8), which rendered the faint band in the 50-kD region
ofthe SDS-polyacrylamide gels ofimmunoprecipitates from
Raji cells more plausible (Fig. 7). However, this component,
like the constitutive phosphoprotein, p130, which also was
not heavily iodinated (Figs. 1-3, 8, and 9) and could not be
visualized after labeling with [35S]methionine (Fig. 5), was
present in sufficient amounts to justify its definite inclusion
in the complex. The p14 component also is not considered
a definite member of the complex; in Raji cells it could be
labeled only with [35S]methionine (Fig. 5), and its relation-
ship to the 'III-labeled p14 of K562 cells is uncertain, espe-
cially as the latter apparently could only be immunoprecipi-
tated with anti-CD19 (Figs. 7 and 9) . Although its molecular
mass is in the range of the y subunit of the Fc, receptor type
I (FcERI) and of the ~ subunit of the TCR complex, it did
not share with these proteins the characteristic of being a
disulfide-linked homodimer (Fig. 10) .
Primary interactions between the members of CR2/CD19
complex were defined by analysis of the K562 transfectants.
Coprecipitating with CD19 from the singly transfected K562
cells expressing this membrane protein were p50, p20, p14,
and possibly p130 (Fig. 8), and coprecipitating with CR2
from the CR2 single transfectants were p130 and p40 (Fig.
7). The p40 component, which was also observed to coprecipi-
tate with CR2 in the presence of NP-40 (Fig. 3), is not part
of the CR2/CD19 complex, and may be related to functions
of CR2 other than modulating [Ca2+];, such as priming
(30), although other explanations for its presence have not
been excluded, such as proteolysis of CR2 or alternative
splicing of CR2 mRNA. Therefore, CR2 does not bring
unique components to the CR2/CD19 complex.
CR2 and CD19 may interact directly in the CR2/CD19
complex, a conclusion that is supported by their 1:1 molar
ratio in the complex. This would be the second specific in-
teraction between members of the Ig superfamily and com-
plement system, the previously defined interaction being that
between Clq and Ig by which the immune system directs
reactions of the complement system. The CR2/CD19 com-
plex differs fundamentally in that it involves membrane rather
than soluble proteins, and it may be a mechanism by which
complement modulates the immune system.
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